vs
ICHOR HOLDINGS, LTD.（ICHR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
ICHOR HOLDINGS, LTD.的季度营收约是再鼎医药的2.0倍（$256.1M vs $127.1M），再鼎医药同比增速更快（17.1% vs 4.7%），ICHOR HOLDINGS, LTD.自由现金流更多（$-10.0M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 12.3%）
Ichor Holdings Ltd.是面向全球半导体制造领域的关键流体输送系统、子系统及相关组件的设计、制造供应商，产品集成于晶圆前端加工设备，为北美、东亚、欧洲的领先半导体设备与芯片厂商提供先进逻辑、存储芯片生产配套支持。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ICHR vs ZLAB — 直观对比
营收规模更大
ICHR
是对方的2.0倍
$127.1M
营收增速更快
ZLAB
高出12.4%
4.7%
自由现金流更多
ICHR
多$16.7M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
12.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $256.1M | $127.1M |
| 净利润 | $-2.5M | — |
| 毛利率 | 12.6% | 51.0% |
| 营业利润率 | 88.2% | -54.6% |
| 净利率 | -1.0% | — |
| 营收同比 | 4.7% | 17.1% |
| 净利润同比 | 45.8% | — |
| 每股收益（稀释后） | $-0.07 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICHRZLAB
| Q1 26 | $256.1M | — | ||
| Q4 25 | $223.6M | $127.1M | ||
| Q3 25 | $239.3M | $115.4M | ||
| Q2 25 | $240.3M | $109.1M | ||
| Q1 25 | $244.5M | $105.7M | ||
| Q4 24 | $233.3M | $108.5M | ||
| Q3 24 | $211.1M | $101.8M | ||
| Q2 24 | $203.2M | $100.1M |
净利润ICHRZLAB
| Q1 26 | $-2.5M | — | ||
| Q4 25 | $-16.0M | — | ||
| Q3 25 | $-22.9M | $-36.0M | ||
| Q2 25 | $-9.4M | $-40.7M | ||
| Q1 25 | $-4.6M | $-48.4M | ||
| Q4 24 | $-3.9M | — | ||
| Q3 24 | $-2.8M | $-41.7M | ||
| Q2 24 | $-5.1M | $-80.3M |
毛利率ICHRZLAB
| Q1 26 | 12.6% | — | ||
| Q4 25 | 9.4% | 51.0% | ||
| Q3 25 | 4.6% | 59.5% | ||
| Q2 25 | 11.3% | 60.6% | ||
| Q1 25 | 11.7% | 63.6% | ||
| Q4 24 | 11.6% | 61.5% | ||
| Q3 24 | 13.2% | 64.1% | ||
| Q2 24 | 12.6% | 64.9% |
营业利润率ICHRZLAB
| Q1 26 | 88.2% | — | ||
| Q4 25 | -6.2% | -54.6% | ||
| Q3 25 | -8.1% | -42.3% | ||
| Q2 25 | -2.0% | -50.3% | ||
| Q1 25 | -0.5% | -53.3% | ||
| Q4 24 | -0.5% | -62.6% | ||
| Q3 24 | -0.2% | -66.6% | ||
| Q2 24 | -1.1% | -76.0% |
净利率ICHRZLAB
| Q1 26 | -1.0% | — | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | -9.6% | -31.2% | ||
| Q2 25 | -3.9% | -37.3% | ||
| Q1 25 | -1.9% | -45.8% | ||
| Q4 24 | -1.7% | — | ||
| Q3 24 | -1.3% | -40.9% | ||
| Q2 24 | -2.5% | -80.2% |
每股收益（稀释后）ICHRZLAB
| Q1 26 | $-0.07 | — | ||
| Q4 25 | $-0.46 | $-0.05 | ||
| Q3 25 | $-0.67 | $-0.03 | ||
| Q2 25 | $-0.28 | $-0.04 | ||
| Q1 25 | $-0.13 | $-0.04 | ||
| Q4 24 | $-0.11 | $-0.09 | ||
| Q3 24 | $-0.08 | $-0.04 | ||
| Q2 24 | $-0.15 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.1M | $689.6M |
| 总债务越低越好 | $6.3M | — |
| 股东权益账面价值 | $668.0M | $715.5M |
| 总资产 | $972.5M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资ICHRZLAB
| Q1 26 | $89.1M | — | ||
| Q4 25 | $98.3M | $689.6M | ||
| Q3 25 | $92.5M | $717.2M | ||
| Q2 25 | $92.2M | $732.2M | ||
| Q1 25 | $109.3M | $757.3M | ||
| Q4 24 | $108.7M | $779.7M | ||
| Q3 24 | $116.4M | $616.1M | ||
| Q2 24 | $114.3M | $630.0M |
总债务ICHRZLAB
| Q1 26 | $6.3M | — | ||
| Q4 25 | $123.5M | — | ||
| Q3 25 | $123.5M | — | ||
| Q2 25 | $125.0M | — | ||
| Q1 25 | $126.8M | — | ||
| Q4 24 | $128.5M | — | ||
| Q3 24 | $130.3M | — | ||
| Q2 24 | $130.2M | — |
股东权益ICHRZLAB
| Q1 26 | $668.0M | — | ||
| Q4 25 | $663.9M | $715.5M | ||
| Q3 25 | $676.2M | $759.9M | ||
| Q2 25 | $694.1M | $791.7M | ||
| Q1 25 | $700.4M | $810.8M | ||
| Q4 24 | $698.3M | $840.9M | ||
| Q3 24 | $697.3M | $667.7M | ||
| Q2 24 | $694.9M | $704.2M |
总资产ICHRZLAB
| Q1 26 | $972.5M | — | ||
| Q4 25 | $942.9M | $1.2B | ||
| Q3 25 | $966.6M | $1.2B | ||
| Q2 25 | $985.1M | $1.2B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $995.6M | $1.2B | ||
| Q3 24 | $975.9M | $985.3M | ||
| Q2 24 | $947.7M | $987.4M |
负债/权益比ICHRZLAB
| Q1 26 | 0.01× | — | ||
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.18× | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 0.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-10.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | -3.9% | -21.0% |
| 资本支出强度资本支出/营收 | 2.8% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-16.8M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ICHRZLAB
| Q1 26 | — | — | ||
| Q4 25 | $9.2M | $-26.0M | ||
| Q3 25 | $9.2M | $-32.0M | ||
| Q2 25 | $-7.5M | $-31.0M | ||
| Q1 25 | $19.0M | $-61.7M | ||
| Q4 24 | $-2.5M | $-55.8M | ||
| Q3 24 | $8.1M | $-26.8M | ||
| Q2 24 | $17.5M | $-42.2M |
自由现金流ICHRZLAB
| Q1 26 | $-10.0M | — | ||
| Q4 25 | $5.9M | $-26.7M | ||
| Q3 25 | $2.1M | $-35.0M | ||
| Q2 25 | $-14.8M | $-33.9M | ||
| Q1 25 | $496.0K | $-63.2M | ||
| Q4 24 | $-6.9M | $-58.4M | ||
| Q3 24 | $2.2M | $-28.2M | ||
| Q2 24 | $14.6M | $-42.9M |
自由现金流率ICHRZLAB
| Q1 26 | -3.9% | — | ||
| Q4 25 | 2.6% | -21.0% | ||
| Q3 25 | 0.9% | -30.4% | ||
| Q2 25 | -6.2% | -31.1% | ||
| Q1 25 | 0.2% | -59.9% | ||
| Q4 24 | -3.0% | -53.8% | ||
| Q3 24 | 1.0% | -27.7% | ||
| Q2 24 | 7.2% | -42.9% |
资本支出强度ICHRZLAB
| Q1 26 | 2.8% | — | ||
| Q4 25 | 1.5% | 0.5% | ||
| Q3 25 | 3.0% | 2.6% | ||
| Q2 25 | 3.0% | 2.6% | ||
| Q1 25 | 7.6% | 1.5% | ||
| Q4 24 | 1.9% | 2.4% | ||
| Q3 24 | 2.8% | 1.3% | ||
| Q2 24 | 1.4% | 0.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICHR
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
